Zacks Small Cap Has Pessimistic View of ARWR FY2025 Earnings

Key Points

• Zacks Small Cap has significantly reduced its FY2025 earnings estimate for Arrowhead Pharmaceuticals, now predicting a loss of ($0.07) per share, down from a previous estimate of $0.30.
• Several analysts have varying opinions on Arrowhead's stock, with price targets ranging from $17.00 to $80.00, and a consensus rating of "Buy."
• Insider trading activity shows that James C. Hamilton, an insider, sold 15,000 shares at $25.00 each, indicating a notable decrease in ownership of the stock.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Equities research analysts at Zacks Small Cap dropped their FY2025 earnings estimates for Arrowhead Pharmaceuticals in a research report issued on Tuesday, September 2nd. Zacks Small Cap analyst D. Bautz now anticipates that the biotechnology company will post earnings per share of ($0.07) for the year, down from their previous estimate of $0.30. The consensus estimate for Arrowhead Pharmaceuticals' current full-year earnings is ($2.42) per share. Zacks Small Cap also issued estimates for Arrowhead Pharmaceuticals' Q4 2025 earnings at ($0.23) EPS, FY2026 earnings at ($0.83) EPS and FY2027 earnings at ($2.62) EPS.

ARWR has been the subject of several other research reports. Citigroup lowered their target price on shares of Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating for the company in a research note on Tuesday, May 13th. TD Cowen upgraded shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a report on Monday, July 28th. B. Riley upgraded shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a report on Monday, August 11th. Royal Bank Of Canada reduced their price objective on shares of Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an "outperform" rating for the company in a research report on Friday, August 8th. Finally, HC Wainwright restated a "buy" rating and set a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, September 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $43.14.

Arrowhead Pharmaceuticals Trading Up 2.0%

ARWR stock traded up $0.55 during mid-day trading on Friday, hitting $28.28. 1,090,364 shares of the company were exchanged, compared to its average volume of 2,028,185. The company has a quick ratio of 4.87, a current ratio of 4.87 and a debt-to-equity ratio of 0.39. The firm has a market capitalization of $3.91 billion, a P/E ratio of -22.09 and a beta of 1.00. The business has a fifty day simple moving average of $19.24 and a 200-day simple moving average of $16.32. Arrowhead Pharmaceuticals has a 12-month low of $9.57 and a 12-month high of $29.34.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last announced its earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share for the quarter, missing the consensus estimate of ($0.94) by ($0.32). The business had revenue of $27.77 million for the quarter, compared to the consensus estimate of $29.01 million. During the same period in the previous year, the business posted ($1.38) earnings per share.

Institutional Trading of Arrowhead Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Virtus Advisers LLC purchased a new position in Arrowhead Pharmaceuticals during the 2nd quarter worth $34,000. GAMMA Investing LLC raised its position in Arrowhead Pharmaceuticals by 297.6% during the 1st quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company's stock worth $28,000 after buying an additional 1,628 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in Arrowhead Pharmaceuticals during the 4th quarter worth $49,000. Nisa Investment Advisors LLC raised its position in Arrowhead Pharmaceuticals by 75.9% during the 2nd quarter. Nisa Investment Advisors LLC now owns 3,032 shares of the biotechnology company's stock worth $48,000 after buying an additional 1,308 shares during the last quarter. Finally, Daiwa Securities Group Inc. raised its position in Arrowhead Pharmaceuticals by 883.3% during the 2nd quarter. Daiwa Securities Group Inc. now owns 4,189 shares of the biotechnology company's stock worth $66,000 after buying an additional 3,763 shares during the last quarter. Hedge funds and other institutional investors own 62.61% of the company's stock.

Insider Buying and Selling

In related news, insider James C. Hamilton sold 15,000 shares of the company's stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $25.00, for a total value of $375,000.00. Following the completion of the sale, the insider owned 247,122 shares in the company, valued at $6,178,050. This represents a 5.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last ninety days, insiders have sold 25,000 shares of company stock valued at $575,000. 4.30% of the stock is owned by corporate insiders.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.